SEngine Precision Medicine raises $3M (round now $8.2M), adds Nobel laureate Lee Hartwell and investor Elliott Burkland to board

SEngine Precision Medicine raised $3 million, bringing its current round to $8.2 million, and appointed former Fred Hutch president and Nobel laureate Dr. Lee Hartwell to its board; new investor Elliott Burkland of Bangarang Group will also join the board. The company uses its PARIS test to grow patients’ tumor cells as organoids and analyze drug combinations to personalize cancer treatment.

No comments yet.